drugset / Trial / NCT01542190

Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery

NCT01542190

Phase 4 Completed 80 enrolled University of Campinas, Brazil
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to compare effects of preoperative and postoperative use of topical ketorolac tromethamine 0.4% versus placebo in uncomplicated cataract surgery. Patients scheduled to undergo phacoemulsification will be randomized to receive either topical prednisolone acetate 1% 4 times daily (QID) plus dextran 70/hypromellose QID (placebo group) or topical prednisolone 1% QID plus ketorolac tromethamine 0.4% QID (ketorolac group) for three days preoperatively and four weeks postoperatively. The primary outcome 5 weeks after surgery will be angiographic cystoid macular edema.

Timeline

Start
2011-02
Primary completion
2012-12
Completion
2013-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketorolac Tromethamine Small molecule 0.4 % Topical

Indications